Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announced that Dr. Osama Hamdy, MD, PhD, has joined its advisory board. Hamdy will act as a consultant and will provide invaluable input regarding key opinion leader studies in both the diabetes and metabolic health fields using Nemaura’s glucose monitoring technology. An acclaimed endocrinologist, Hamdy is medical director of the Obesity Clinic Program at the Joslin Diabetes Center; he is also an associate professor of medicine at Harvard Medical School. He has built a stellar reputation as a world-renowned thought leader in obesity management in diabetes, medical nutrition and digital health, and has impacted the space through many discoveries and innovations. He provides expertise in understanding metabolic and cardiovascular benefits of lifestyle changes and weight loss with current research in the cardiovascular benefits of short- and long-term weight reduction in obese individuals with and without type 2 diabetes. “We are truly gratified to have a practicing clinician that has changed the real-world treatment of diabetes management as an advisor to us for some upcoming KOL studies,” said Nemaura CEO Dr. Faz Chowdhury in the press release. “These studies will allow us to better impact patient health, and we expect the counsel and input from Dr. Hamdy to be meaningful in helping us to deliver non-invasive treatment options to further enrich people’s lives.”
To view the full press release, visit https://ibn.fm/aK0ZZ
About Nemaura Medical Inc.
Nemaura Medical is a medical technology company developing and commercializing noninvasive wearable diagnostic devices. The company is currently commercializing sugarBEAT(R) and proBEAT(TM). sugarBEAT, a CE mark-approved class IIb medical device, is a noninvasive and flexible continuous glucose monitor (“CGM”) that provides actionable insights derived from real-time glucose measurements and daily glucose trend data, which may help people with diabetes and prediabetes to better manage, reverse and prevent the onset of diabetes. Nemaura has submitted a PMA (premarket approval application) for sugarBEAT to the U.S. Food and Drug Administration (“FDA”). proBEAT combines noninvasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the United States as a general wellness product as part of NMRD’s BEAT diabetes program. Nemaura sits at the intersection of the global type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50-plus billion prediabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023. For more information about the company, visit www.NemauraMedical.com.
NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork